Literature DB >> 15528793

Diagnostic application of hMLH1 methylation in hereditary non-polyposis colorectal cancer.

Nagahide Matsubara1.   

Abstract

Colorectal cancer (CRC) due to mismatch repair (MMR) defect has distinct characteristics among unselected CRCs. These CRCs are biologically less aggressive and, thus, showing better prognosis but less sensitive to the 5FU-based chemotherapy. CRCs with MMR defect derive from both hereditary and sporadic reasons. Germline inactivation of MMR genes (hMLH1, hMSH2, hMSH6, and hPMS2) underlies the hereditary CRC with MMR defect (Lynch syndrome) and epigenetic silencing of hMLH1 gene causes the sporadic CRC with MMR defect. Hereditary and sporadic CRC with MMR defect can be detectable by microsatellite instability (MSI) test or immunohistochemical analysis among general CRCs. Lynch syndrome can be diagnosed by the clinical criteria or by genetic test to detect pathogenic germline mutations in MMR genes. However, both clinical criteria and genetic test are inadequate for the diagnosis of Lynch syndrome. Since genetic test for the diagnosis of the Lynch syndrome is expensive and not always identify pathogenic germline mutations, effective and inexpensive screening program is desirable. Here we propose a possible application of methylation test combined with MSI or pathological analysis as an effective and a cost-saving new strategy for screening of Lynch syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528793      PMCID: PMC3839271          DOI: 10.1155/2004/371941

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  2 in total

1.  Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease.

Authors:  William B Coleman; Ashley G Rivenbark
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

Review 2.  A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.

Authors:  Margot G F van Lier; Anja Wagner; Monique E van Leerdam; Katharina Biermann; Ernst J Kuipers; Ewout W Steyerberg; Hendrikus Jan Dubbink; Winand N M Dinjens
Journal:  J Cell Mol Med       Date:  2009-11-19       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.